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Abstract The safety of ADHD medications is not fully
known. Concerns have arisen about both a lack of con-
temporary-standard information about medications ﬁrst
licensed several decades ago, and signals of possible harm
arising from more recently developed medications. These
relate to both relatively minor adverse effects and extre-
mely serious issues such as sudden cardiac death and
suicidality. A guidelines group of the European Network
for Hyperkinetic Disorders (EUNETHYDIS) has therefore
reviewed the literature, recruited renowned clinical sub-
specialists and consulted as a group to examine these
concerns. Some of the effects examined appeared to be
minimal in impact or difﬁcult to distinguish from risk to
untreated populations. However, several areas require fur-
ther study to allow a more precise understanding of these
risks.
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Introduction
Attention-deﬁcit hyperactivity disorder (ADHD) is one of
the most common mental disorders with a worldwide mean
prevalence of around 5% in children [109] and 3% among
adults [40]. The disorder persists into adulthood in a sig-
niﬁcant proportion of the affected individuals and, most
commonly, its course is complicated due to frequent
comorbidities and impaired psychosocial functioning.
Thus, ADHD requires continuing professional care on the
level of both assessment and intervention. Guidelines help
clinicians to provide high-quality care to their patients by
delivering evidence-based state of the art management
strategies. This European guidelines group has contributed
to the process through previous publications [13, 140].
It is widely accepted that intervention in ADHD should
be based on multimodal treatment. Amongst its various
components, drug treatment is of speciﬁc value and rele-
vance to the patients. Accordingly, methylphenidate, dex-
amfetamine and atomoxetine in particular are widely used
in European countries and North America for the treatment
of ADHD. They are effective drugs, and meta-analyses
investigating their use have led to our guidelines recom-
mending their use as part of a comprehensive treatment
programme [13, 140].
TherearehundredsoftrialsinvolvingtheADHDdrugs,allof
them indicating that they are associated with a range of adverse
effects that are generally acceptable,because theyare mildand/
ortemporary.Thesehavebeensummarisedinotherreviews:for
example, Graham and Coghill [49] describe several domains
being involved. These symptoms predominantly include neu-
rological effects (headache, dizziness, insomnia, seizures);
psychiatric effects (mood/anxiety, tics, psychotic symptoms);
and gastroenterological effects including poor appetite and
overlapping with possible growth restriction. Whilst the
majority of evidence addresses a similar age group and devel-
opmental span (middle childhood and adolescence) there are
also data to inform relative risks of prescription of stimulants
andatomoxetine inyoungerage groups [6,74]—which suggest
greater sensitivity to emotionality following prescription of
either drug—as well as suggestions that older/adult groups and
cognitively impaired individuals may also display differential
risks (although these are not well evidenced).
Despite existing literature, there are residual concerns
that the true safety of these drugs is not fully known. For
the most commonly used drug, methylphenidate, intro-
duction and licensing of the original immediate release
form came in the 1960s, and hence before modern stan-
dards of clinical trials and post-licensing surveillance were
established. Also the introduction and regulatory approval
of newer forms of the drugs, which have been accompanied
by enhanced standards of monitoring, have resulted in
signals of potential harm, raising the possibility that some
of these adverse outcomes may also apply to methylphe-
nidate. For example, of all spontaneous reports of adverse
drug reactions in Denmark between 1998 and 2007, drug
reactions were classed as ‘serious’ when reported in 52 and
18 children taking methylphenidate and atomoxetine,
respectively [5]. Public and professional concern has been
raised about the potential for severe reactions, even
including death, and for the generation of misuse. These
uncertainties make it possible either that vulnerable chil-
dren are being exposed to unreasonable hazard, if real risks
go undetected, or that children are being denied the beneﬁt
of medication if perceived risks are exaggerated.
We have therefore reviewed the published literature on
adverse effects of the drugs that are licensed in Europe, and
most commonly used, for the treatment of ADHD or
hyperkinetic disorder. As such we have speciﬁcally exam-
ined: immediate release methylphenidate, modiﬁed release
methylphenidate, dexamfetamine and mixed amfetamine
compounds,andatomoxetine.Severaldrugsarenotlicensed
in Europe and are either unavailable (e.g. guanfacine), or
uncommonly used (e.g. modaﬁnil, clonidine and tricyclic
antidepressants). These unlicensed drugs were not included
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123in the review, but are referred to where relevant to under-
standing of the recommended medications. We have focus-
sed on safety in children and adolescents, but the review has
been additionally informed byadultdata.Meta-analysis was
not feasible because of heterogeneity in information repor-
ted; where quantitative data are available we have used the
indices reported in the papers. In addition to addressing the
published literature we requested information from the
licence holders about unpublished safety information. The
Eunethydis ADHD Guidelines Group (EAGG) meeting was
in part supported by the pharmaceutical industry and Long-
term Effect of Psychotropic Medication in Children Clinical
Research Group of UK Mental Health Research Network
(including some travel and hotel costs). In preparing for the
meeting, companies were requested to supply: data sent to
the European Medicines Agency (EMA), all published
papers,postersandsubmittedmanuscriptsconcerningsafety
issueswiththeirproduct(s)relatedtoADHDtreatment.Data
submitted to the EMA were not given to the group, but the
remaining items were provided. In addition, all companies
were invited to make a presentation at the EAGG meeting
and/or answer speciﬁc questions from the group. The man-
uscript submitted for publication was sent to all companies
for comment with the decision to revise being held by
EAGG. We also consulted specialists in paediatrics, cardi-
ology and endocrinology; and held a series of consensus
conferences, examining incidence, causality and potential
impactofrisks,throughwhich wehave formulatedadviceto
clinicians about the frequency and severity of each and the
means of reducing harm or reacting to adverse events if they
should occur. The evidence and advice will be divided into
the main different areas of concern.
Cardiac adverse events
The cardiac safety of drugs used to treat ADHD remains of
concern to many prescribers and families, following reports
of sudden cardiac deaths of individuals taking drugs for
ADHD. Stimulants are also well known to exert both
pressor and chronotropic cardiac effects. Child and ado-
lescent psychiatrists and paediatricians who are aware of
black box advisory labels and advice to monitor cardiac
parameters may remain uncertain as to the true risks in both
cardionormal children and those with existing risk factors.
Frequency of cardiac adverse events in treated
and untreated populations
Sudden death in children and adolescents
In contrast to adults, sudden death occurs only rarely in the
general paediatric population. Sudden death rates range
from 0.8 to 8.5/100,000 patient-years [20, 30, 98, 99, 159].
The median of these published sudden death rates in chil-
dren is at 1.2–1.3/100,000/year. Sudden death in children
and adolescents is associated with both known and previ-
ously unrecognized cardiac conditions. Among young
persons with known congenital heart disease, the highest
risks of sudden death (0.2% per year) occur with speciﬁc
conditions such as aortic stenosis [128].
In children with ADHD, the risk of death from all causes
is estimated at 58.4/100,000 patient-years [157], whereas
the risk of sudden unexplained death is unknown. The Food
and Drugs Administration (FDA) in the USA, and Health
Canada identiﬁed 25 sudden deaths in individuals pre-
scribed ADHD medications from post-marketing data
between 1999 and 2003, raising concerns of a possible
association. 12 of these individuals were in the 1–18 years
bracket. However, when the number of patient-years of
prescribed medication was incorporated into the evalua-
tion, the frequency of reported sudden death per year of
ADHD therapy with methylphenidate, atomoxetine or
amfetamines among children was 0.2–0.5/100,000 patient-
years [99]. The analysis of 10-year adverse-event reporting
in Denmark resulted in no sudden deaths in children taking
ADHD medications [5]. While it is recognised that
adverse events are frequently under-reported in general, it
is likely that sudden deaths in young individuals on rel-
atively new medications may be better reported. Death
rates per year of therapy, calculated using the adverse
events reporting system (AERS) reports and prescription
data, are equivalent for two ADHD drugs (dexamfetamine
and methylphenidate): 0.6/100,000/year [37]. (The accu-
racy of these estimates is limited however, for instance
because in moving from number of prescriptions to
patient-year ﬁgures assumptions must be made about the
length of each prescription). It seems likely, using these
best available data, and assuming a 50% under-reporting
rate, that the sudden death risk of children on ADHD
medications is similar to that of children in general.
Caveats to the above include the observation that 2 of the
25 sudden deaths on ADHD medication occurred with
initiation of stimulant medication. Thus, as with most
therapies, an exceedingly rare but real risk of sudden
death cannot be completely excluded. If childhood deaths
on ADHD medications are under-reported to a greater
degree than we have assumed, then some incremental risk
could potentially be present.
A recently published study compared stimulant use in
two matched groups of 564 young people aged 7–19 years:
one group who had suffered sudden unexplained death, and
the other who had died as passengers in motor vehicle
accidents [48]. Stimulant use was found in 10 (1.8%) of the
former group versus 2 (0.4%) of the latter group. The odds
ratio was reported to be 7.4 (95% CI 1.4–74.9); from which
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with sudden death. The FDA, however, has suggested
caution in interpreting these ﬁndings, citing possible
methodological ﬂaws. In addition, the physical and mental
health comorbidities associated with the disorder that
requires stimulant treatments may themselves increase the
risk of sudden death from other causes.
In another study the incidence of sudden death in chil-
dren prescribed ADHD drugs was not found to be statis-
tically different to that in the general population; but this
study was limited by its sample size [91]. As sudden death
in children is so rare, very large epidemiological studies are
required to adequately examine this question. At the time
of writing, some studies of ADHD medication risk remain
pending, and practice should be reassessed in the event of
any new convincing data. For example, the FDA is cur-
rently conducting a large epidemiological study (500,000
patients) to further examine this question.
Hypertension
The deﬁnition of hypertension in children (blood pressure
beyond the 95th centile for age and height) suggests that
about 5% of children would technically be hypertensive to
a level requiring investigation and possible treatment
(including pharmacotherapy) prior to administration of
stimulant drugs. In theory, every childhood population
should have this number of children receiving measures to
reduce their blood pressures below the 95th centile (and
below the 90th centile if there is evidence of end organ
damage) [4]. In practice, however, routine screening for
and treatment of hypertension in children has not been
widely implemented as a public health standard of care.
The actual values for blood pressure at the various per-
centiles differ slightly in European countries [62, 75, 88],
so local norms should be used wherever possible. The
average blood pressure in children is increasing; perhaps in
part due to increased prevalence of obesity [97].
All stimulant medications and atomoxetine are reported
to cause elevations in blood pressure [150]. While the
average increases range from 1–4 mmHg systolic and
1–2 mmHg diastolic, this small average change includes
patients where the rise in blood pressure is more signiﬁ-
cant, and there are also data showing increases above the
95th centile in individuals taking ADHD medications. For
categorically measured hypertension, controlled trial data
are available for atomoxetine and indicate that elevations
above the 95th percentile are seen in 6.8% of patients
(systolic) and 2.8% (diastolic), in comparison to 3 and
0.5%, respectively, of patients treated with placebo [150].
Categorical hypertension data for methylphenidate are not
published so far but are likely to be of a similar order of
magnitude on the basis of the changes in mean pressures.
The patient information leaﬂet for methylphenidate prod-
ucts in Europe indicates that the drug may increase systolic
and diastolic blood pressure by more than 10 mmHg.
1
Heart rate increases
Stimulant and non-stimulant medications are recognised to
cause a small increase in heart rate averaging 1–2 beats per
minute [146, 150]. The averaging of data in clinical studies
can hide a small proportion where the increment is larger;
indeed up to 50 beats/min in rare cases [150].
QT interval prolongation
Prolongation of the QTc interval in individuals (without a
congenital long QT syndrome or previously recognised
long QT interval) can be caused by a variety of medications
and is a recognised risk factor for ventricular tachyar-
rhythmias and sudden death [160]. Thus, the potential
effects of ADHD medications on the QT interval are
important given the concerns raised about the safety of this
group of medications. The average QTc interval is not
changed signiﬁcantly by any of the drug groups (methyl-
phenidate, mixed amfetamine salts and atomoxetine).
However, as with raised blood pressure, the average
changes in any study cohort may not identify signiﬁcant
increases in a subgroup of individuals which are averaged
out by decreases in another subgroup. More important than
the average change in a study cohort is the proportion with
an increment in QTc to above the safe threshold (usually
accepted as being above 470–500 ms). Such data for the
various preparations are available to regulatory organiza-
tions but are not yet in the public domain. Unless new data
emerge for a particular subgroup, there is currently no
indication to monitor for QTc changes when stimulants are
prescribed. Finally, it should be noted that measurement of
the QTc interval is not without difﬁculties, and at least six
alternative methods of rate correction are available [83,
149].
QTc prolongation (and sudden death and increased heart
rate) have been reported with methylphenidate and dex-
amfetamine [99] and atomoxetine [34]. The assessment of
sudden deaths with relation to patient-years of treatment
described atomoxetine deaths at 0.5 per 100,000 patient-
years, and methylphenidate at 0.2 per 100,000 patient-years
[5]. Overall, however, insufﬁcient data exist to truly
demonstrate any differential sudden death risk for different
drugs. A recent retrospective study concluded that expo-
sure to methylphenidate and amfetamine salts showed
similar risks for cardiac emergency department visits [158].
1 http://www.ema.europa.eu/htms/human/referral/article31/methyl-
phenidate.htm.
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Sudden death, whether occurring in children or adults, is of
course a disastrous event. That individuals with an unde-
tected cardiac pathology, such as a cardiomyopathy or
conduction problem, might as a result of ADHD medica-
tion, have their illness at best ‘revealed’ or at worst
aggravated with a potentially fatal outcome, remains to be
excluded as an extremely rare possible outcome.
Despite the lack of a public health approach to hyper-
tension in younger people, it is recognised that intimal
plaque formation may occur as a result of hypertension in
children [19], and in the long-term even small increases of
blood pressure are associated with an increased incidence
of cerebrovascular disease in adults [81]. Other conse-
quences include end organ damage such as: left ventricular
hypertrophy, retinopathy, and nephropathy with protein-
uria. In adults a 2 mmHg lowering of usual systolic blood
pressure would result in about 10% lower stroke mortality
and about 7% lower mortality from ischemic heart disease
or other vascular causes in middle age [81].
In terms of potential mechanisms whereby ADHD
medications may cause cardiac risk, any persistent heart
rate increases seen with ADHD treatment are usually very
small and unlikely to be a risk factor for exacerbation of
underlying cardiac pathology, but a less common larger
persistent rise in heart rate may theoretically do so. Simi-
larly, signiﬁcant QTc prolongation (to intervals above
470–500 ms) is known to result in a risk of potentially fatal
arrhythmias, such as Torsade de Pointes [100].
A personal history of cardiac symptoms (e.g. syncope on
exercise) and a positive family history of sudden death
below the age of 40 years, or of death associated with
exercise are particular risks for sudden death. This risk
might potentially be increased by treatment by drugs with
pressor adverse effects, although evidence is lacking, and
sudden death more commonly will be the ﬁrst presentation
of the underlying condition. Other risks include pre-exist-
ing arrhythmias and channelopathies (e.g. long QT
syndrome).
With respect to hypertension, an elevated blood pressure
before ADHD treatment or appearing in the course of
treatment, a positive family history and other risk factors
for cardiac disease are likely to mediate risk. Another
mediator may be obesity; children with a BMI above the
95th percentile had a hypertension prevalence of 10.7% in
one study; in contrast to children with a BMI below 85th
percentile, who had a hypertension prevalence of only
2.6% [130].
It is not known whether children with ADHD have a
coexisting increased incidence of hypertension, although
there is evidence of a link [66]. The confounder is of course
stimulant therapy in this population.
In the FDA post-marketing reports, many of the iden-
tiﬁed subjects were receiving polypharmacy, which there-
fore may moderate risk of sudden death. Finally,
cytochrome P450 (CYP 2D6) metaboliser status has been
shown to be a modifying factor in the adverse effects of
atomoxetine [93].
Management of cardiac risk
For ADHD patients without known heart disease—the
ADHD specialist, whether psychiatrist or paediatrician—is
the appropriate person for evaluation of beneﬁt and risk,
and the making of recommendations for medication
therapy.
Congenital heart disease patients have a slightly higher
incidence of ADHD [127], and those affected might well
beneﬁt from ADHD therapies; including appropriately
prescribed medication. During such treatment, input from a
paediatric cardiologist/electrophysiologist may be useful,
although the ADHD specialist remains the appropriate
individual to evaluate the beneﬁt and risk and make rec-
ommendations for medication therapy in this case. In a
setting where there may truly be a risk of sudden death (e.g.
the congenital long QT syndrome), a frank discussion of
these aspects between the family, ADHD specialist and
paediatric cardiologist or electrophysiologist should help to
reﬁne the acceptability for the individual patient.
Pre-treatment checking and monitoring of pulse and
blood pressure are recommended with any ADHD medi-
cation in all patients with ADHD, with frequency of
monitoring thereafter usually arbitrarily recommended as
either three [67] or six monthly [140], but clearly this
requirement may vary in individual cases. Sustained ele-
vated blood pressure before or on treatment with stimu-
lants requires assessment and treatment. Blood pressure
should be measured prior to treatment and at each visit
and converted to a centile score using the appropriate
chart. If the ﬁrst recording is elevated then it should be
repeated at least twice and if still elevated, and above the
95th centile, then referral to a paediatric hypertension
specialist is required, for 24-h ambulatory blood pressure
recordings to conﬁrm the diagnosis and to initiate any
investigations for end organ damage. In patients already
treated for ADHD, alternatively, a dose reduction or drug
holiday could be proposed before referring to the spe-
cialist, the latter principally to conﬁrm the potential role
of the drug in the hypertensive state. Further management
will depend on the severity of the blood pressure elevation
and in consultation with the ADHD specialist might
include antihypertensive treatment in addition to the
stimulants, or discontinuation of the medication. A ﬂow
chart for both the ADHD specialist and hypertension
specialist is attached (Fig. 1).
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signal for a cardiac review. New-onset palpitations
should be managed as for unmedicated patients: occa-
sional extra beats are not necessarily a cause for con-
cern, but persistent tachycardia could be due to
arrhythmia and needs investigation. In 2008 the Amer-
ican Heart Association initially recommended ECG as a
standard part of the assessment for treatment for ADHD,
prior to then changing this to be at the discretion of
the clinician [147]. ECG screening is, however, not
currently considered cost-effective or appropriate for
prevention of sudden death in the general paediatric
population in Europe (or the US), for example, as
reported by Denchev et al. [32] in a recent economic
evaluation of the issue. The issue of ECG in identiﬁ-
cation of at-risk individuals participating in competitive
sport (also discussed by Denchev) is separate to the
remit of this paper; and insufﬁcient evidence exists to
conﬁrm the combination of ADHD medication and
exercise as representing an increased risk. Our view
in summary therefore is that there is no current evidence
to suggest an incremental beneﬁt for routine ECG
assessment of ADHD patients prior to initiation of
medication.
Suicide-related events
‘Suicide-related events’ are not only self-destructive acts
but also include suicidal ideation, plans and beliefs in the
pointlessness of life. It is generally accepted that an
assessment of suicidality is an important part of psychiatric
evaluation, either via general enquiry or via structured
rating scales such as the Columbia suicide rating scale
[111]; suicidal thoughts are not necessarily associated with
a depressive disorder. Systematic review has indicated that
there is a relationship between the presence of ADHD itself
and suicidal attempts [161]; so it should not automatically
be assumed that any suicidal thinking or attempt is an
adverse effect of medication. In terms of severity and
impact, most reports to the Multimodal Treatment Study of
Children with ADHD (MTA) were of mild and transient
symptoms that did not require hospitalisation [1]. There
were no completed suicides.
Frequency of suicidality reports
Suicide-related events are rarely associated with ADHD
drug treatment. Speciﬁc ﬁgures for stimulants are not
publically available; however, summaries of product
Fig. 1 Recommendation for blood pressure (BP) monitoring and management in ADHD patients
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contain cautions about suicidality as a possible adverse
effect.
In September 2005 the United States Food and Drug
Administration (FDA) added a ‘black box’ warning to the
product labelling of atomoxetine [Eli Lilly and Co.,
Strattera safety information, 2006 (online)], based on an
analysis of adverse-event data from the atomoxetine clin-
ical trials database, which identiﬁed a small but statistically
signiﬁcantly increased risk of suicidal thoughts among
atomoxetine-treated children and adolescents compared
with patients in those trials taking placebo. A meta-analysis
of the data showed that suicidal ideation was more fre-
quently observed in clinical trials among children and
adolescents treated with atomoxetine (5/1,357) compared
to those treated with placebo (0/851), with a number nee-
ded to harm (NNH) of 227 compared to the number needed
to treat (NNT) of 5 to achieve remission of ADHD
symptoms [15]. There was one suicide attempt in the ato-
moxetine-treated group and no completed suicide occurred
during the trials. In adults treated with atomoxetine there
was no evidence of increased suicidal risk.
Data from population-based studies indicate that self-
reported suicide-related events are common in young
people who have neither been diagnosed with, nor treated
for, ADHD. For example, the rate of self-harm in UK
11–15 year olds with no mental disorder was 1.2, 9.4% in
those with anxiety disorders, 18.8% in children with
depression, 12.6% in those with conduct disorder and 8.5%
among children with hyperkinetic disorder [92]. In con-
trast, the prevalence of suicide-related behaviour in chil-
dren treated with ADHD drugs from RCTs is reported as
only 0.4% [144]. While this low observed event rate in
trials is likely to reﬂect the exclusion of suicidal subjects
from entering trials, a short time base, and a lack of sys-
tematic assessment and reporting, there is little or no
compelling evidence to suggest that the observed event rate
of suicide-related events in children treated with ADHD
drugs is greater than the expected (background) rate in the
general population.
Causality and factors mediating risk
Various emotional and behavioural changes are occasion-
ally described in children treated with ADHD medications
including: anxiety, agitation, panic attacks, insomnia, irri-
tability, hostility, aggressiveness, impulsivity, akathisia
(psychomotor restlessness), hypomania and mania. These
could in principle be markers to the states of distress that
can lead to suicidal acts; but no causal link between the
emergence of such symptoms and the emergence of sui-
cidal impulses has been established. Comorbidities occur-
ring with ADHD (such as depression and conduct disorder)
may in themselves be associated with an increase in the
risk of suicidal ideation and/or behaviour.
Management of suicide risk
A psychiatric history is of course routinely needed before
prescription of any medication. In view of uncertain
degrees of risk, caution is required when prescribing
ADHD drugs to children and young people with a past
history of serious suicidal attempt or depression.
Families and caregivers should be advised of the need to
recognise any emergence of emotional change or self-
injurious thinking; and to communicate well with the pre-
scriber [144]. Patients being treated with ADHD drugs
should be observed for the emergence of suicide-related
events. If they do emerge in treatment, consideration
should be given to dose reduction and/or other changes in
the therapeutic regimen, including the possibility of dis-
continuing the medication; especially if these symptoms
are severe or abrupt in onset, or were not part of the
patient’s presenting symptoms. Psychiatric evaluation (or
re-evaluation) should be arranged and the patient’s pro-
gress carefully monitored.
Growth in childhood
Poor growth is a common concern in the treatment of
ADHD, especially with children already on the lower
growth percentiles; but the impact of medication on growth
in weight and height has remained somewhat unclear.
There are outstanding questions as to whether ADHD in
itself is an independent risk factor for poor growth, and
whether individuals showing a slowing of growth whilst on
medication return to their previous growth trajectory
eventually or on discontinuation of medication.
Evidence of impact on growth, and possible causal
mechanisms
Studies providing longitudinal data suggest that treating
children with ADHD with stimulant medication generally
results in a reduction in both height and weight gain [37,
112]. On average, the reduction in height amounts to
approximately 1 cm/year during the ﬁrst 1–3 years of
treatment [42]. The reduction in weight gain appears to be
somewhat more pronounced than that for height (over a
3-year period about 3 kg less than predicted) [39, 139].
Stimulant treatment does not, however, appear to
markedly increase the number of children who fall below
the ﬁfth percentile of the population [37]. Effects are
usually minor, but there is substantial variability: some
children are completely unaffected, whereas for others
Eur Child Adolesc Psychiatry (2011) 20:17–37 23
123treatment results in signiﬁcant growth suppression. Current
data indicate that the initial effect of stimulants on growth
appears to attenuate over time [39, 114, 139] and early
studies of the adult outcomes of children treated with
stimulant medications have suggested that ﬁnal adult
height is not affected [55, 71]. Nevertheless, follow-up
periods are not yet sufﬁciently long enough, nor the sample
sizes big enough, to allow ﬁrm conclusions to be drawn.
Most studies do not suggest differences in the magnitude
of growth deﬁcits between methylphenidate and dexamfe-
tamine[108].Smalleffectswereseenforatomoxetineduring
the ﬁrst 2 years of treatment; but in those who received
prolongedtreatmentforupto5 yearsnolong-termeffectson
growth were apparent apart from an overweight subgroup
[133, 134]. These two parts of the same study are probably
not yet sufﬁcientevidence forrulingoutgrowthproblems as
an adverse effect of atomoxetine, and indeed there is one
study describing the medication as an effective adjunct to
weight loss in obese women [45] (with similar studies
examining similar outcomes for stimulants [61, 78]).
It is possible that the effects of stimulants on growth are
dose-dependent.Signiﬁcanteffectsonweightandheightmay
require average doses of methylphenidate exceeding 1.5 mg/
kg per day which are given continuously [28, 132]. Effects
maybegreaterforchildrenthanadolescents,butoverallthere
aretoofewstudiestoallowﬁrmconclusionsineitherofthese
areas. Preschool children may be particularly vulnerable to
growth effects: the National Institute of Mental Health Pre-
school ADHD Treatment Study reported that children
between 3 and 5 years of age treated with methylphenidate
had annual growth rates 20.3% less than expected for height
(1.38 cm/year) and 55.2% for weight (-1.32 kg/year) [138].
Causality and factors mediating risk
Reduced caloric intake and suboptimal nutrition due to
appetite suppression are likely causes of growth suppres-
sion. Hypothetically, dysregulation of receptors in the
growth system could also be responsible; adaptation of
receptors could contribute to tolerance to growth inhibition
over time and to catch-up growth after the medication has
been discontinued. Acute effects on growth hormone and
prolactin have been observed, but do not yet explain per-
sisting growth deﬁcits [18, 37, 84]. A hypothesis that
ADHD itself is associated with dysregulated growth, either
decreased [54, 131] or increased [138, 139] has been put
forward, but current evidence is contradictory.
Management of growth risks
Physicians should advise patients and their parents about
the potential for growth delay with medication use and
discuss the balance between these effects and the potential
outcomes that may result from non-treatment. A growth
chart should be used to monitor height, weight and appetite
in all medication-treated children and adolescents at least 6
monthly [140]. Should growth deﬁcits occur during treat-
ment, various clinical strategies might be considered.
Current data do not support speciﬁc guidelines indicating
what magnitude of height or weight gain deceleration
should trigger changes in the treatment regimen, but simple
strategies to improve nutrition can be implemented. These
may include coordinating the timing of doses (e.g. taking
the ﬁrst dose after breakfast) and meals (e.g. late evening
meal) and encouraging the use of high-energy, nutritious
snacks. These clinical strategies would be expected to
reduce growth deﬁcits, but no studies have yet examined
this hypothesis directly. Periods of treatment cessation
(drug holidays) seem to result in rebound growth for
children who experienced deﬁcits during treatment, with
children seeming to return to their normal growth percen-
tiles and trajectory [37, 112]. Drug holidays, however, can
also be problematic for the child and family because the
ADHD symptoms will often re-emerge or worsen during
the period that medication is withheld. For individual
patients, physicians need to balance the risk of exacerbat-
ing the child’s ADHD symptoms, by lowering the dose or
switching to a different medicine, against the risks asso-
ciated with growth delays. Decisions should be based on
the clinical considerations of the individual patient. If there
is serious concern about growth, referral to a paediatric
endocrinologist is warranted. Criteria for referral can fol-
low the medical guidelines concerning referral for short
stature and consideration of growth hormone supplemen-
tation in adults and children, which are as follows [46]:
• height [1.5 SDs below the average of mother’s and
father’s height;
• height[2 SDs below the population mean plus a 1-year
height velocity [1 SD below the mean or a 1-year
decrease of[0.5 SD in height;
• a 1-year height velocity[2 SDs below the mean, or a
2-year height velocity[1.5 SDs below the mean.
Further research is needed into the causal mechanisms,
and the long-term implications of continuous treatment
from childhood to adulthood for ultimate height.
Sleep disturbance
As is the case for several of the other adverse events, an
important initial point to make is that sleep disturbance
may be associated both with ADHD medication, and
the condition of ADHD itself. For example, a recent
meta-analysis [31], based on 16 methodologically sound
studies published between 1987 and 2008, showed that
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more impaired than healthy controls in parentally reported
items of problematic behaviours around bedtime and in the
early morning. These children were also impaired in some
actigraphic and polysomnographic measures indicating
fragmented sleep and poor sleep efﬁciency, sleep disor-
dered breathing, and excessive daytime sleepiness [122].
However, the pooled analysis of all data on sleep archi-
tecture gave contradictory results about any alterations in
REM sleep and no alterations on percentage of slow wave
sleep. Some conditions associated with ADHD (such as
anxiety) can also lead to poor sleep. The effect of sleep
impairment differs greatly from one individual to another,
but can be distressing to both the child and the family and
may give rise to behavioural and learning difﬁculties in the
daytime [103, 107].
Frequency of sleep problems
Stimulants
Clinical experience suggests that psychostimulant medi-
cation may negatively impact on sleep, but the effects vary
considerably from one patient to another. An observational
report suggested that some patients with ADHD are able to
get to sleep easily within just a few hours of taking a dose
of stimulant medication, others need an interval of up to
6–8 h [25]. However, a review of scientiﬁc studies com-
paring medicated and unmedicated children describes
inconsistent outcomes, both for polysomnographic mea-
sures and for parental reports [123].
In a review of subjective reports on medicated versus
unmedicated children with ADHD there were high rates of
parental report of sleep problems, but few of these were
conﬁrmed by objective sleep data [29]. In a placebo-con-
trolledcross-overactigraphicmonitoringstudyof44children,
sleep latency was similar in children with ADHD on meth-
ylphenidate versus placebo, but total sleep duration was
shorterwithmethylphenidatethanplacebo[125].However,a
smaller, non-actigraphic study suggested that methylpheni-
date does not appear to affect sleep patterns adversely and
possibly normalizes them in patients with ADHD [142].
Sleep problems may therefore primarily be related to
ADHD severity and comorbidity and not to medication.
Among individual sleep parameters, difﬁculty falling
asleep continues to differ signiﬁcantly between children
with or without medication after the severity of ADHD
symptoms has been controlled for [142].
Nonstimulant medications
In a randomized, double-blind, cross-over study comparing
the effect of methylphenidate (given thrice daily) and
atomoxetine (given twice daily) on the sleep of children
with ADHD, methylphenidate increased sleep-onset
latency signiﬁcantly more than did atomoxetine, both
considering actigraphic and polysomnographic data [123].
Moreover, both childrens’ diaries and parents’ reports
indicated a better quality of sleep (in terms of ‘‘getting
ready in the morning’’, ‘‘getting ready for bed’’, ‘‘falling
asleep’’) with atomoxetine, compared with methylpheni-
date. Both medications decreased night-time awakenings,
but the decrease was greater for methylphenidate. Clearly,
these results from a single study need to be replicated.
Causality and factors mediating risk
Stimulants most likely increase wakefulness via their
sympathomimetic action and as such are used in treatment
of narcolepsy [2]. Several factors that may mediate the
effects of stimulant medications on sleep have been iden-
tiﬁed. In one study, depressive symptoms contributed sig-
niﬁcantly to the degree of sleep disturbance when
controlling for ADHD diagnosis and methylphenidate
treatment [136]. Some studies assessed the effect of stim-
ulants given in two doses (morning and noon). It is possible
that sleep problems may be linked to restlessness linked to
the rebound effect more than to the direct action of stim-
ulants [26]. Some authors have reported that a small dose
of methylphenidate taken before bedtime can facilitate
sleep [64, 70]. Other studies, however, using a third dose at
the end of the day did ﬁnd a greater sleep-onset delay in
children treated with stimulants compared to untreated
subjects [7, 137].
Management of sleep problem risks
Given the limited number of studies and the contradictory
ﬁndings, guidelines for the management of sleep distur-
bances associated with ADHD cannot be properly evidence
based. A history of any sleep problems should be taken
before starting medication, and if this is a severe/signiﬁcant
issue, it may suggest atomoxetine as a ﬁrst line choice. If
problems arise during medication, then sleep diaries are
recommended. Sleep hygiene and behaviour therapy tech-
niques based on stimulus control, and appropriate bedtime
scheduling,shouldbeencouragedforchildrenwithsleep-onset
problems and/or possible delayed sleep phase syndrome.
A switch of medication should be considered when sleep
problems persist after careful dose adjustment and dose-
scheduling of the original medication; for instance, patients
taking a stimulant medication might switch to atomoxetine.
Although clonidine is outwith the main focus of this paper,
some evidence exists to suggest it may be effective in
ADHD with associated sleep problems [153]. Recent
research has also shown that melatonin is effective in
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could be considered a reasonable therapeutic approach
[17].
Tics and Tourette’s syndrome
In tic disorders (TD), co-existence with ADHD can be
found in about 50% of patients, while in ADHD patients a
TD is seen in about 20%: Both ﬁgures are above the chance
rate of combination [121]. The use of licensed ADHD
drugs (both stimulants and atomoxetine) in the presence of
tics remains subject to debate. Some experts describe an
increase in tics when drugs are given, others do not. Sev-
eral physician’s desk references and drug administration
mandates still note a contraindication for the use of stim-
ulants in patients with TD [110, 121]; and even in those
with only a family history of tics. Fortunately, in recent
updates this is no longer the case [49, 140], but taking a
history of tics and close monitoring of coexisting tics are
mandatory (see decision of the European Commission for a
new wording of European Drug Administration Mandates
being harmonized all over Europe, Homepage of EMEA
2009).
Several recent reviews [24, 119, 124] indicate that
stimulants are adequately safe in patients with both ADHD
and TD and should not be disregarded when planning
treatment for ADHD in these individuals. In terms of the
impact of TD, the psychosocial functioning of ADHD ?
TD children is usually not worsened signiﬁcantly when tic
exacerbation by drugs takes place, since ADHD is com-
monly the more impairing disorder [117, 118]. Rarely,
stress-sensitivity may increase, but there will usually be
enough time to come to a joint treatment decision with
families balancing the risk–beneﬁt ratio.
Frequency and causality
Dopamine-receptor antagonists may decrease tics, while
drugs which increase dopamine activity may precipitate or
exacerbate tics. The precipitation of ﬁrst-onset tics during
treatment with methylphenidate was found not to be dif-
ferent from placebo (range 0–20%), according to a review
that examined predominantly short-term studies, but
included up to 4 years’ duration of monitoring [119]. The
literature on exacerbation of pre-existing tics by stimulants
indicates that about 5–10% of cases may get worse with
stimulants; independent of initial tic severity. This exac-
erbation, if it occurs, is fully reversible after stimulant
withdrawal or dose reduction [104, 110]. Moreover, clini-
cal experience suggests that with improvement of attention
and self-regulation by stimulants the control of tics may
itself improve. In the controlled studies of atomoxetine, its
impact on tics was either not different from placebo or even
showed some positive effect on tic frequency [8, 110, 135].
On the other hand, a few case reports have described
exacerbation of tics during atomoxetine treatment [43, 77,
79, 105, 106, 126]. This might reﬂect dopamine imbalance
in certain patients, which is in line with the theory that
stimulants might lead to further activation of an already
hyperactive meso-striatal dopaminergic system in TD,
where higher doses of stimulant compounds may provoke a
higher frequency of tics.
Management of tics during ADHD treatment
Because tics are naturally waxing and waning, it is often
difﬁcult to decide if a worsening of tics is provoked by a
drug. Therefore, a long-term observation of at least
3 months is sometimes required before a clinical decision
can be made. ADHD and TD can be considered within the
framework of an additive model [14, 121]. It follows, that
the symptoms may be treated with a separate but parallel
approach, i.e. in addition to stimulants or atomoxetine for
ADHD, treatment with antipsychotic medication may help
to reduce tics. The latter suggestion is not evidence based,
being derived from the experiences of clinical experts only;
but meanwhile it has been included in clinical guidelines
[120]. It can be assumed that the effect on tic exacerbation
is similar for both methylphenidate and dexamfetamine.
For atomoxetine, however, the situation may be more
favourable, although the negative case reports cannot be
neglected. For clonidine, which is only occasionally used
in Europe to treat TD and/or ADHD, but recommended by
some authors (especially where TD is the predominant
disorder) [116], there exists some evidence that it may
reduce tics in frequency and severity, as well as improve
ADHD symptoms; but on the other hand, worsening of tics
may be seen in about a quarter of cases [3].
Substance abuse, misuse and diversion
Substance use disorder (SUD) is a maladaptive pattern of
non-medical use of substances leading to functional
impairment and/or risks over the past 12 months. Sub-
stance dependence is differentiated from abuse by the
presence of drug tolerance, preoccupation with drug
seeking and drug taking, and continued use despite
knowledge of risks and despite repeated attempts to stop
(as opposed to simply use associated with various risks and
actual harms). Concurrence of ADHD and SUD has been
consistently observed for many years and there is an
ongoing debate on the question whether medication treat-
ment of ADHD, with stimulants in particular, changes the
risk for patients to develop SUD. Concerns exist both as to
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sons, such as to aid weight loss (misuse), and also as to the
use of medications by individuals for whom they were not
speciﬁcally prescribed (diversion). Findings from preclin-
ical research have suggested that animals exposed to
stimulants become ‘‘sensitized’’: subsequent administration
results in more robust behavioural responses, and/or they
become more likely to self-administer drugs of abuse later
in development [72, 73].
Comorbid risk and estimates of frequency of abuse
Several epidemiological studies compare ADHD subjects
with unaffected groups, and ﬁnd hazard ratios for SUD
varying from 1.2 to 3 [22, 35, 95] and up to 7.9 for drug
dependence [68]. Even a single symptom of ADHD or
conduct disorder (CD) may be associated with an increased
risk for SUD [35]: hyperactivity symptoms uniquely con-
tributed to subsequent initiation of all types of substance
use, to nicotine dependence, and cannabis abuse/depen-
dence, even after controlling for CD, whereas impulsivity
predicted alcohol misuse [36]. Based on follow-up data
from the MTA study, signiﬁcantly higher rates of child-
reported lifetime substance use at age 13 were reported in
ADHD patients compared to a local normative comparison
group (HRs 2.3) [94]. Probands with ADHD who did not
differ from those without ADHD in absolute rates of SUD,
still had an earlier onset, a longer duration, and higher rates
of severely impairing SUD as well as higher rates of
alcohol and drug dependence than non-ADHD children
[23]. Correspondingly, the prevalence of childhood and
adult ADHD in the substance-abusing population has been
estimated to be about 3 times that in the general popula-
tion: for instance, adults with a lifetime diagnosis of
cocaine and/or opioid dependency show an ADHD lifetime
prevalence of 5.2%, compared to 0.85% in individuals
without SUD [10].
Do stimulants increase the risk of SUD?
Whether stimulant medication adds to the risk for sub-
stance abuse is not clear; several studies suggest it does
not. A meta-analytic review of six studies suggested that
stimulant therapy in childhood may be associated with a
reduction in risk, compared to unmedicated ADHD sub-
jects, for subsequent drug and alcohol use disorders
(HR = 1.9), with a stronger effect during adolescence
(HR = 5.8) than adulthood follow-up (HR = 1.4) [155];
however, when this group was re-examined a further
5 years later no signiﬁcant differences were found that
might represent a difference in substance use risk [21]. The
reduction in risk might be attributable to treatment rather
than stimulant medication in particular: the MTA study
found a reduction in risk for those patients treated with
behaviour therapy; medication had no effect one way or the
other [94]. No difference in substance use was observed in
patients with developmental reading disorder (but without
ADHD), previously treated with methylphenidate or pla-
cebo for up to 18 weeks, suggesting that neither sensiti-
zation nor protective effects can be related to stimulant
treatment per se [85]. Other studies show either no inﬂu-
ence of methylphenidate or a reduction of risk; in one study
only when stimulant treatment had been initiated before
puberty [21, 38, 53, 65, 86].
Putative mediating processes
With regard to potential mediating factors, gender and the
presence and severity of CD/antisocial personality disorder
or delinquency appear to be the moderating variables for
the risk of subsequent SUD in ADHD patients; and these
effects are stronger than any inﬂuence of medication [16].
In ADHD subjects, both genetic predisposition and social/
environmental factors interact to determine persistence of
conduct symptoms and antisocial behaviours [27, 101,
129], which are then important inﬂuences on substance
abuse and misuse.
Euphoric properties and reinforcing effects of methyl-
phenidate are associated only with intravenous injection or
nasal inhalation and not with oral administration [148].
Euphoria is practically unknown with oral methylpheni-
date; though the situation with dexamfetamine is unclear,
because of lack of study rather than conﬂicting ﬁndings.
Misuse or diversion of stimulants has been reported in
adolescents and young adults in North America, either in
order to improve academic performance (studying, staying
awake, improved alertness) or in the context of a SUD
[145, 152, 156].
Prevention and management of comorbid SUD, misuse
and diversion
Early recognition and treatment, perhaps combined with
longer term behaviour therapy and/or longer term/contin-
uous medication treatment, may reduce the risk for SUD in
ADHD patients. Depending on the speciﬁc situation, cur-
rent or previous substance abuse in the family can be seen
as either a relative contraindication for stimulant pre-
scription, especially in the immediate release preparation,
or as a reason for extremely close monitoring of a patient’s
stimulant use. The extended-release formulations of stim-
ulants are less prone to diversion because these prepara-
tions cannot easily be crushed into powder for injection or
snorting, and also because the once-a-day administration
makes parental supervision easier to enforce. Based on
preclinical, short-term clinical data and abuse liability
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appear to be associated with risk for substance use disor-
ders and may well be preferred in high-risk cases [63].
Use of cannabis is not necessarily a contraindication to
prescribing stimulant medication, and a pragmatic
approach will be required. The other dangers of cannabis,
however, should not be ignored and patients will need to be
warned of these. Cocaine, however, is likely to be a real
hazard in view of its sharing neurochemical effects with
dopaminergic drugs, and the two should not be combined.
Epilepsy and seizures
Childrenwithepilepsiesshowa3-to5-foldhigherprevalence
of ADHD than controls [33]. Among the various psycho-
pathological features of the epilepsies, ADHD is the most
frequent comorbidity. ADHD patients have been shown to
have incidence rates of unprovoked seizures and epilepsy as
many as two to three times greater than non-ADHD children
[58]. Although epileptic disorders affect *1% of the paedi-
atric population, the evidence base for ADHD treatment in
children with epilepsies is disproportionately thin.
There are occasionally concerns that, as with other
psychotropics, ADHD medications may lower the seizure
threshold so as to cause seizures in previously seizure-free
individuals. However, in prospective trials, retrospective
cohort studies and post-marketing surveillance in ADHD
patients without epilepsies, the incidence of seizures did
not differ between ADHD pharmacotherapy and placebo
[relative risk (RR)] for current versus non-use for meth-
ylphenidate, 0.8; RR for atomoxetine, 1.1 [90, 151].
Methylphenidate has been shown to prolong the duration of
kindled seizures in rats [11]. Amfetamine has the potential
to both increase and decrease seizure risk in animals [50,
69]. In rodents treated with atomoxetine, seizure induction
occurred only with doses several-fold higher than the
highest approved dose for humans [143].
Mediating inﬂuences
Higher overall seizure rates are reported from untreated
ADHD patients with epilepsy compared to similar but medi-
cation-treatedADHDpatients[90];itisunclearwhetherthisis
due to a reluctance to administer ADHD medication to chil-
drenatriskforepilepsyorto riskfactors mitigated byADHD
treatment(e.g.substanceabuse).Anelevatedriskforseizures
can be associated with antiepileptic drug (AED) polyphar-
macy, mental retardation, neurologic deﬁcits, metabolic dis-
eases, congenital anomalies, and other developmental
disorders [90]. Available evidence does not support an
increased risk in seizure-free ADHD children with centro-
temporal (rolandic) spikes [56, 59].
Differential drug effects
There is substantial evidence for short-term efﬁcacy of
methylphenidate in children with epilepsies, while no nega-
tive effects on seizures and EEG abnormalities have been
observed, and indeed there is some evidence for possible
beneﬁts in some cases [42, 51, 52]. A larger systematic
review did not ﬁndevidencefor meaningfulpharmacokinetic
or pharmacodynamic interactions between methylphenidate
and AEDs [87]. Foramfetamine, effects oncomorbid ADHD
and epilepsies are not yet systematically evaluated. Response
rates incaseseries reports are disappointing,but these reports
are biased since they almost exclusively included non-
responders to methylphenidate [47, 102]. Amfetamine seems
to have an anticonvulsant effect in patients with nocturnal
seizures and a favourable impact on drowsiness induced by
AEDs [9, 41, 82]. In several retrospective case series reports
of previous methylphenidate non-responders with epilepsy,
atomoxetine showed disappointing response rates and high
rates of discontinuation [143]. Limited evidence from pro-
spective case series reports in children with epilepsy is more
promising, but a seizure increase may occur in a minority of
cases [57]. For amfetamine and atomoxetine, efﬁcacy and
short-term safety have yet to be established in stimulant-
naive patients with infrequent seizures. As with methylphe-
nidate, preliminary evidence supports efﬁcacy on ADHD
symptoms and a low seizure risk in patients with infrequent
seizures. Studies in children with more active epilepsy seem
justiﬁed.
Management of seizure risks
Adolescents with epilepsies are at increased risk for
depression and suicidal ideation [12]. During ADHD
treatment, they should therefore be monitored for the
emergence of depression, irritability and suicidal ideation.
A careful evaluation of the potential beneﬁts and risks of
pharmacotherapy seems warranted in preschool ADHD
children, in whom epilepsies may still be recognised for the
ﬁrst time during their further development. Fatal hepato-
toxicity has been reported as an extremely rare event in
young epileptic children with polypharmacy or inborn
errors of metabolism. Regarding the combination of ato-
moxetine with antiepileptic agents that might increase the
risk for liver toxicity, patients should be carefully moni-
tored clinically. Elevation of liver enzymes, however, is a
poor predictor of impending hepatotoxicity.
Besides speciﬁc pharmacotherapy, it has been shown that
symptoms of inattention, impulsivity and restlessness in epi-
lepsymaybeimprovedbynon-speciﬁc interventions,suchas
better seizure control, decreasing AED polypharmacy,
reducingdruginteractions,andswitchingtoAEDswithfewer
cognitive and behavioural effects [143].
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The term ‘psychosis’, as a reported adverse event, is
deﬁned at the level of symptoms and does not imply a
full-blown psychotic disorder. Psychotic symptoms
include hallucinations or delusions occurring in clear
consciousness, neither associated with fever nor transi-
tions to or from sleep. Adverse-event reporting of ‘psy-
chosis’ frequently also includes symptoms of mania,
hypomania and ‘agitated states’. In terms of the severity
of impact of these symptoms, most reports from the
FDA analysis described below [96]w e r eo fm i l da n d
transient symptoms that did not require hospitalisation or
treatment.
Frequency
Data from population-based birth cohorts indicate that self-
reported psychotic symptoms are common and may occur
in up to 10% of 11-year-old children [115]. In contrast, the
prevalence of psychotic symptoms in children treated with
ADHD drugs from RCTs is reported as only 0.19% [39].
While this very low observed event rate in trials is likely to
reﬂect a lack of systematic assessment and reporting, there
is no compelling evidence to suggest that the observed
event rate of psychotic symptoms in children treated with
ADHD drugs exceeds the expected (background) rate in the
general population. In the US FDA analysis, ADHD drug
overdoses did not contribute signiﬁcantly to reports of
psychosis adverse events.
Psychotic symptoms are rarely associated with ADHD
drug treatment. The United States Food and Drugs
Administration (FDA) [96], reviewed 49 RCTs of ADHD
drugs in children and found a total of 11 psychosis/mania
events during 743 person-years of exposure with ADHD
drug treatment compared to no psychosis events reported
with placebo. From these data, the psychosis event rate is
1.48 per 100 person-years, or one event in every 70 years
of treatment with a number needed to harm (NNH) of 526.
The FDA also reviewed industry post-marketing sur-
veillance case reports in the United States for ADHD drugs
prescribed in children and adults between 2000 and 2005
and found 865 reports of psychosis events [144]. Half of
these reports occurred in children under the age of
10 years. Although the exact denominator (prescribing
frequency) is unknown for post-marketing surveillance
reports, if we assume a prescribing frequency of 3 per 100
school age children in the United States this results in a rate
of reported psychosis events of 1 in 2,500 treated cases of
ADHD.
Psychotic adverse events have been reported in associ-
ation with dexamfetamine, methylphenidate, and ato-
moxetine. The FDA review of ADHD drug RCTs, with
regard to the ADHD drugs reviewed in this report, reported
the highest psychosis adverse event rate with MPH (in the
form of transdermal patches, not currently licensed in
Europe) (13.2/100 person-years) followed by dexamfeta-
mine (2.0/100 person-years) and atomoxetine (0.8/100
person-years). No psychosis adverse events were reported
in 11 RCTs of oral methylphenidate (immediate and
modiﬁed release) and 4 RCTs of mixed amfetamine salts
(Adderall XR).
Mediating mechanisms
Amfetamine increases synaptic release of dopamine in the
mesolimbic system and is associated with increased posi-
tive psychotic symptoms in patients with schizophrenia
[76]. Hence, there is a plausible neurobiological mecha-
nism that could link stimulant drugs with psychotic
symptoms. However, this evidence all comes from studies
in adults and in those with a pre-existing psychotic disorder
and consequent increased vulnerability to psychotic
symptoms. It is unclear whether a similar risk applies to
children and those without an increased biological vul-
nerability to psychosis. Interestingly, half of the US FDA
post-marketing surveillance reports of psychotic symptoms
occurred in young children (under age 10) who would
typically be viewed as being less vulnerable to dopamine-
mediated drug-induced psychosis than adolescents or
adults [39].
Theoretically, at least, evidence of vulnerability to
psychosis in terms of a positive family history or prior
psychotic episodes may increase the risk of psychotic
symptoms with ADHD drugs.
Management of risk of psychosis or mania
The evidence of an increased risk of psychotic symptoms
associated with ADHD medications is weak. Reported
psychosis adverse events are rare and much less common
than the expected rate of self-reported non-clinical psy-
chotic symptoms in the general child population. The
impact of reported psychosis adverse events in most cases
is mild and most are self-limiting. If psychotic symptoms
do occur with ADHD drugs, then they could in very rare
circumstances represent an adverse drug reaction or
symptom of a psychotic disorder, but consideration should
be given to the more likely possibility that psychotic
symptoms are common phenomena in children and in most
circumstances will be unrelated to either ADHD drugs or a
psychotic disorder. Nevertheless, and in view of potentially
increased vulnerability to psychosis with ADHD drugs,
caution would be appropriate when prescribing ADHD
drugs to children and young people with a family history of
psychosis or past history of psychotic episodes.
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of ADHD drugs?
The structured interruption of a pharmacological treatment
(often called a drug holiday) occurs when a patient stops
taking medication(s) for a period of time. In general, drug
holidays can be very short (a few days) or very long
(months or even years). Drug holidays are commonly used
in a range of therapeutic domains. Clinical anecdote and
informal report suggests to us that drug holidays are quite
commonly used in relation to ADHD medication. Drug
holidays can have various functions, and in relation to
ADHD treatment these can be divided into four types.
First, drug holidays anecdotally have been used to
counteract waning effectiveness after a period of continu-
ous use; perhaps by interrupting the development of pos-
sible tolerance and/or the need to continually increase the
dose over time. Second, they can be used to monitor
whether medication is still effective after a period of long-
term treatment or whether the balance between side effects
and therapeutic effects is still in favour of continued
treatment. Third, they can be used to allow ‘normal’ life to
resume either for activities to be undertaken without the
effects of symptom control being apparent—some indi-
viduals prefer to not take medication to be ‘themselves’, to
play sport, etc.—or for there to be no need to remember to
take tablets. Finally, drug holidays can be used to control
acute adverse events (e.g. poor sleep and reduced appetite)
and reduce their chronic effects (e.g. reduced growth or
long-term increases in blood pressure).
Despite the potential value of drug holidays and the
likelihood that they are used frequently, either formally or
informally, as part of ADHD medication regimen, there is
very little data on issues such as the extent of their use; the
factors that predict use (e.g. child characteristics, parent
and clinician’s beliefs, disorder progression, social struc-
tures and cultural norms); or their effectiveness in terms of
either enhancing or reducing clinical effects or reducing
side effects and their adverse consequences.
Systematic study of these three questions seems espe-
cially important now because not only has consideration of
drug holidays been recommended on pragmatic grounds
[37, 113, 140], but also because of their potential frequent
use; especially as parents (and/or patients) may often ini-
tiate drug holidays independently without the clinical
guidance or approval [60, 89, 154].
Evidence for drug holidays
In the only randomized controlled trial addressing the issue
of drug holidays and ADHD drug adverse effects, patients
were randomized to receive either BID methylphenidate
7 days a week or 5 days a week and a weekend drug
holiday when placebo was administered in a double-blind
design [89]. No reduction in therapeutic effects on week-
ends (as rated by parents) or on the following day of school
(as rated by teachers) was found, but despite this, fewer
sleep and appetite side effects were reported. Observational
studies have also focused on the longer term effects of drug
holidays on growth. A study on the effects of long-term (at
least 21 months) use of OROS methylphenidate on the
growth of children and adolescents reported relatively
small effects of methylphenidate on overall height and
weight and a slight beneﬁcial effect of drug holidays;
however, these effects were not signiﬁcant [132]. In a
similar study comparing amfetamine and methylphenidate
in children treated for at least 1 year, small effects of drug
dose were found on height and weight but there was no
effect of the duration of treatment or the use of drug hol-
idays [55].
Risk–beneﬁt balance
The risk–beneﬁt balance of drug holidays must be taken
into account, and there are risks attached to the intermittent
cessation of treatment. For instance, a review of the rela-
tionship between ADHD and burn accidents reported that a
high proportion of children visiting burns units had not had
their usual dose of medication on the day of the visit [44,
141]. Furthermore, the health economic costs per year to
accident emergency departments were higher when chil-
dren were not receiving their normal medication [80].
In summary to date, and despite their theoretical bene-
ﬁts, the evidence that drug holidays can help control side
effects is very limited. The database needs to be expanded
in a number of ways. First, the Martins et al. [89] ﬁndings
of the possible beneﬁts of 5-days-a-week administration
need to be replicated; second, longer term studies need to
be conducted using randomized and quasi-randomized
designs; third, the range of adverse effects studied in
relation to drug holidays needs to be extended (to include
for instance cardiac effects). Fourth, the differential impact
of ‘informal’ parent/patient-initiated and ‘formal’ clini-
cian-initiated holidays should be studied. Fifth, the pre-
dictors of drug holiday effectiveness need to be examined.
Sixth, beneﬁts and costs of drug holidays need to be
assessed systematically.
Issues lacking evidence and future evidence sources
A recurring theme in this paper is that there is particular
uncertainty about possible adverse effects that are rare and
severe. The most extreme is sudden death; which, as con-
sidered above, is so uncommon that extremely large
numbers of subjects will be needed to detect whether the
30 Eur Child Adolesc Psychiatry (2011) 20:17–37
123risk is raised above the base rate in the general population.
Liver failure presents a similar uncertainty for the clinician:
rare cases have been reported in people taking atomoxe-
tine. They may well be no more common than in the
population as a whole, but no conclusion is possible. The
probability of under-reporting, and the lack of information
about the usual prevalence of otherwise unexplained liver
failure, leave real uncertainty. We can recommend only
that the clinician should be vigilant for early signs of dis-
ease—which would include persistent and unexplained
malaise as well as the more obvious features such as
jaundice, dark urine, or itching—and investigate with liver
enzyme tests if they appear. In the UK, the former Com-
mittee on Safety of Medicines has stated that families
should be warned in advance of the necessity for medical
advice if any of these signs should appear.
Another kind of uncertainty arises from possible prob-
lems for which good measurement has not previously been
available. There could be long-term changes in the brain—
for instance, in neurotransmitter levels or receptor den-
sity—but adequate techniques of investigation are only
now becoming available. We do not know if such changes
occur; if they do, whether they are related to medication or
to the condition itself; if they are caused by medication,
whether they have functional signiﬁcance; and whether any
changes are helpful or harmful to mental development.
This is not to argue that the effects are harmful; to the
contrary, our clinical experience of long-term medication
has not uncovered concerns of cognitive malfunction or
brain damage. Rather, it is to point to the need for research
on possible subtle changes, whether for good or for ill.
Neuropsychological instruments should be developed to
test speciﬁc hypotheses about potentially harmful effects.
New techniques are appearing that could in principle allow
prediction of individuals’ vulnerability to adverse effects.
Pharmacogenomics, repeated monitoring of blood levels of
ADHD compounds, and neuroimaging of the brain’s
response to medication could all earn a place in clinical
practice. For the moment, however, we see them as
opportunities for translational research, not recommenda-
tions for practice.
For many clinicians, the balance of risk against possible
beneﬁts of treatment will be seen as favourable in most
cases, but with a caveat that there are several areas of
uncertainty about the nature of these risks. This review
should help in this regard, but as already discussed each
area still requires further clariﬁcation from pharmaco-epi-
demiology. The concept of ‘willingness to pay’ may have
value when applied to the question of what level of adverse
effects is acceptable for a given treatment beneﬁt for an
individual person. Responsive discussion with patients and
their families is important. Monitoring should include not
only the blood pressure and growth measures already
mentioned, but also common symptoms such as headache,
insomnia, anorexia, nausea and emotional upsets; and any
speciﬁc problems emerging in the individual patient. As
ever, the primary responsibility for ensuring the safety of
the patient lies with the prescriber.
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